CHRISTOPHER DAVIS: Open Payments
NPI 1265483283 · SALISBURY, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$956 in 50 payments from 17 companies in 2025. Trend: 2023 $386 · 2024 $542 · 2025 $956
Food & beverage: $956
| Company | Payments | Amount |
|---|---|---|
| ViiV Healthcare Company | 10 | $192 |
| Gilead Sciences, Inc. | 7 | $162 |
| Lilly USA, LLC | 5 | $88 |
| ABBVIE INC. | 3 | $69 |
| AstraZeneca Pharmaceuticals LP | 4 | $60 |
| PFIZER INC. | 3 | $58 |
| Novo Nordisk Inc | 3 | $51 |
| Astellas Pharma US Inc | 2 | $45 |
| Biogen, Inc. | 2 | $43 |
| Merck Sharp & Dohme LLC | 2 | $39 |
Products named: DOVATO, MOUNJARO, RUKOBIA, Veozah, SKYCLARYS, PIFELTRO, ELIQUIS, MAVYRET.
Industry payments across MD — which companies pay providers there.
